Four biotech firms file for IPOs as 2026 biotech listing surge continues

2026 has seen more than 25 biotech companies debut on public markets, marking the highest number of IPOs since 2021. The wave of listings has helped the sector recover from a slowdown in 2025.

Four additional drugmakers announced plans to go public: AI‑focused Iambic Therapeutics, siRNA specialist ADARx Pharmaceuticals, immunology player TRex Bio, and cardiovascular company Retension Pharmaceuticals.

Industry observers note the momentum. Jack Bannister of Leerink Partners said recent IPOs have priced above their offer levels and are trading well, suggesting the trend could extend through the fall months.